These antitumour effects were closely correlated with IFN-γ responses of OVA-Ip (tumour)-specific CD8+ T cells, which was not affected by anti-IL-6 Ab administration (Fig. 2d), although aged CD8+ T-cell responses were decreased as compared with young ones because of their quantitative decline in CD8+ T cells13. The gene discussed is CD8A; the disease is neoplasm.